Wells Fargo & Company Boosts uniQure (NASDAQ:QURE) Price Target to $75.00

uniQure (NASDAQ:QURE) had its target price upped by research analysts at Wells Fargo & Company from $60.00 to $75.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 84.93% from the company’s previous close.

A number of other equities analysts also recently commented on QURE. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research note on Wednesday, June 17th. Barclays decreased their price target on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday. The Goldman Sachs Group raised their price objective on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, June 18th. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research note on Wednesday. Finally, HC Wainwright boosted their price objective on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $65.00.

uniQure Trading Up 1.2%

NASDAQ QURE traded up $0.49 during mid-day trading on Thursday, hitting $40.56. The company’s stock had a trading volume of 281,133 shares, compared to its average volume of 2,566,476. uniQure has a 52-week low of $8.73 and a 52-week high of $71.50. The stock’s fifty day simple moving average is $36.75 and its two-hundred day simple moving average is $26.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market capitalization of $2.56 billion, a P/E ratio of -11.53 and a beta of 0.90.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.50 million. During the same period last year, the firm earned ($0.69) earnings per share. Research analysts expect that uniQure will post -3.39 EPS for the current year.

Insiders Place Their Bets

In related news, insider Kylie O’keefe sold 15,936 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the completion of the transaction, the insider owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. This represents a 12.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Walid Abi-Saab sold 45,000 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the sale, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. This trade represents a 20.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 433,229 shares of company stock valued at $17,944,799. Insiders own 4.65% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the third quarter worth $50,000. Torren Management LLC acquired a new stake in uniQure in the fourth quarter valued at $28,000. IFP Advisors Inc bought a new position in uniQure during the 4th quarter valued at $48,000. Smartleaf Asset Management LLC bought a new position in uniQure during the 4th quarter valued at $48,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in uniQure by 42.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure said U.S. and U.K. regulatory submissions for AMT-130 remain on track for the third quarter of 2026. The company also expects to report four-year clinical data in September, creating potentially important catalysts for investors. uniQure outlines AMT-130 BLA this quarter, supported by cash runway into 2030
• Positive Sentiment: Management indicated that an FDA advisory committee meeting is expected for AMT-130. While an advisory committee is not a regulatory approval, the event could provide greater visibility into the therapy’s benefit-risk profile and approval prospects. AdCom expected for uniQure’s Huntington’s gene therapy
• Positive Sentiment: uniQure ended the quarter with $810.3 million in cash, cash equivalents and current investments after a $259 million follow-on offering. Management expects these resources to fund projected operating expenses into 2030, reducing near-term financing risk and supporting a potential AMT-130 launch. uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
• Positive Sentiment: AMT-260 produced early biological signals in a Phase I/IIa epilepsy study: three of six low-dose patients experienced 79% to 100% reductions in disabling seizures during months four through six, with a favorable initial safety profile. The data remain preliminary but add value to uniQure’s pipeline. uniQure N.V. Q2 2026 Earnings
• Neutral Sentiment: Second-quarter revenue rose to approximately $5.8 million from $5.3 million a year earlier and exceeded consensus estimates, but the company continues to operate at a substantial loss.
• Negative Sentiment: uniQure reported a $1.22 per-share loss, wider than the approximately $0.81–$0.82 consensus estimate and the $0.69 loss in the prior-year quarter. Net loss increased to $81.1 million from $37.7 million, highlighting ongoing commercialization and development costs. uniQure Reports Q2 Loss, Misses Revenue Estimates
• Negative Sentiment: Reported insider activity showed selling without purchases during the past six months, including sales by senior executives. Such activity may weigh on sentiment, although it does not necessarily reflect the company’s operating outlook.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.